Clovis Oncology, Inc. (NASDAQ:CLVS) has been assigned a consensus rating of “Buy” from the sixteen ratings firms that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $63.00.
A number of research analysts recently weighed in on CLVS shares. Bank of America Corporation reissued a “buy” rating and set a $75.00 price target on shares of Clovis Oncology in a research report on Wednesday, May 17th. Piper Jaffray Companies set a $77.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a report on Tuesday, March 28th. J P Morgan Chase & Co set a $72.00 price objective on shares of Clovis Oncology and gave the stock a “buy” rating in a report on Thursday, June 1st. ValuEngine upgraded shares of Clovis Oncology from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Goldman Sachs Group, Inc. (The) raised their price objective on shares of Clovis Oncology from $44.00 to $75.00 and gave the stock a “neutral” rating in a report on Wednesday, March 15th.
Shares of Clovis Oncology (CLVS) traded up 0.45% during midday trading on Monday, reaching $59.97. 1,968,734 shares of the company’s stock traded hands. Clovis Oncology has a 12 month low of $11.57 and a 12 month high of $74.94. The stock’s market cap is $2.68 billion. The stock has a 50 day moving average of $54.46 and a 200-day moving average of $55.14.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.43) by $0.10. The firm had revenue of $7.05 million for the quarter, compared to the consensus estimate of $6.04 million. On average, equities research analysts forecast that Clovis Oncology will post ($4.95) EPS for the current fiscal year.
In related news, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $47.39, for a total transaction of $142,170.00. Following the completion of the sale, the insider now directly owns 203,583 shares in the company, valued at approximately $9,647,798.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last 90 days, insiders sold 9,000 shares of company stock valued at $495,690. Company insiders own 17.40% of the company’s stock.
A number of large investors have recently bought and sold shares of CLVS. Ladenburg Thalmann Financial Services Inc. raised its stake in Clovis Oncology by 20.0% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 400 shares in the last quarter. First Mercantile Trust Co. purchased a new stake in Clovis Oncology during the first quarter worth approximately $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Clovis Oncology by 71.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,819 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 758 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Clovis Oncology by 3.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 100 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in Clovis Oncology during the first quarter worth approximately $185,000. Institutional investors own 97.55% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was first posted by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.wkrb13.com/markets/2231040/clovis-oncology-inc-clvs-given-consensus-recommendation-of-buy-by-analysts.html.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2231040/clovis-oncology-inc-clvs-given-consensus-recommendation-of-buy-by-analysts.html
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.